ZYTIGA ® (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer
We report late toxicity of a prospective Phase I/II trial employing an MRI assisted focal boost integrated with HDR brachytherapy alone for treatment of low and intermediate risk prostate cancer.
Conclusion: A greater understanding of the molecular events associated with antioxidants will enhance the development of treatment and could result in better strategies for the chemoprevention of prostate cancer. Recent patents also suggest that anti-oxidant compounds can be effective for the prevention and the treatment of prostate cancer. PMID: 29446748 [PubMed - as supplied by publisher]
This article is protected by copyright. All rights reserved.
Most health authorities do not recommend screening for prostate cancer with PSA tests in asymptomatic patients who are not at increased risk. However, opportunistic screening for prostate cancer is still wante...
As a tumor suppressor candidate gene, NPRL2 has anti-cancer effects against several cancers, but its potential role in prostate cancer (PCa) has not been reported. The present study aimed to explore the expression of NPRL2 in PCa and its potential clinical significance. Our results showed that expression of NPRL2 in PCa tissues was significantly higher than in non-PCa tissues (P
Authors: Agbemenu K Abstract This research was conducted to identify the acculturation and health behaviors in the African Immigrant population, which is presently living in the United States. Ten studies met the criteria and included health behaviors of status, access to health care, psychiatric services, prostate cancer, morbidity and mortality, HIV knowledge and beliefs, perceptions of suicide, smoking, and obesity. Acculturation was measured using the most common social constructs that influenced the health behaviors of nativity, English (language proficiency), age at immigration, education and socioeconomic st...
ConclusionsMultimodal modular exercise in prostate cancer patients with bone metastases led to self-reported improvements in physical function and objectively measured lower body muscle strength with no skeletal complications or increased bone pain.Trial Registration: ACTRN12611001158954. Purpose The presence of bone metastases has excluded participation of cancer patients in exercise interventions and is a relative contraindication to supervised exercise in the community setting because of concerns of fragility fracture. We examined the efficacy and safety of a modular multimodal exercise program in prostate cancer pa...
ACS Medicinal Chemistry LettersDOI: 10.1021/acsmedchemlett.8b00003
The US Food and Drug Administration (FDA) has approved the oral agent apalutamide (Erleada) for the treatment of nonmetastatic castration-resistant prostate cancer. The oral androgen-receptor inhibitor is the first FDA-approved treatment for patients with nonmetastatic castration-resistant disease and the first to be approved based on the endpoint of metastasis-free survival.
A genetic mutation linked to ovarian and prostate cancers and passed through the X-chromosome, has been identified, researchers announced.